Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$39.62 +2.6%	$32.24	$16.50 ▼ $43.58	$3.36B	N/A	11,504 shs	5,786 shs
AKBA Akebia Therapeutics	$3.88 -0.5%	$3.37	$1.07 ▼ $4.08	$1.02B	0.88	3.15 million shs	1.87 million shs
PTCT PTC Therapeutics	$48.53 +0.8%	$48.76	$29.02 ▼ $58.38	$3.82B	0.5	876,179 shs	552,502 shs
RARE Ultragenyx Pharmaceutical	$27.41 +0.4%	$35.83	$26.85 ▼ $60.37	$2.58B	0.26	963,114 shs	2.15 million shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	+2.59%	-2.75%	+25.22%	+111.65%	+3,961,999,900.00%
AKBA Akebia Therapeutics	-0.51%	-2.51%	+10.86%	+88.35%	+175.18%
PTCT PTC Therapeutics	+0.81%	-2.00%	-4.56%	+2.41%	+41.94%
RARE Ultragenyx Pharmaceutical	+0.37%	-11.67%	-25.23%	-23.20%	-37.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AKBA Akebia Therapeutics	3.7025 of 5 stars	3.6	1.0	0.0	4.0	2.2	0.8	0.6
PTCT PTC Therapeutics	4.4761 of 5 stars	4.3	1.0	0.0	4.4	3.1	0.8	1.3
RARE Ultragenyx Pharmaceutical	4.4617 of 5 stars	4.5	1.0	0.0	3.8	2.8	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.00	Buy	N/A	N/A
AKBA Akebia Therapeutics	3.20	Buy	$6.75	73.97% Upside
PTCT PTC Therapeutics	2.67	Moderate Buy	$65.00	33.94% Upside
RARE Ultragenyx Pharmaceutical	2.93	Moderate Buy	$83.64	205.15% Upside

Current Analyst Ratings Breakdown

Latest AKBA, PTCT, RARE, and AAPG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	RARE Ultragenyx Pharmaceutical	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$35.00 ➝ $34.00
7/14/2025	RARE Ultragenyx Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$65.00 ➝ $55.00
7/10/2025	RARE Ultragenyx Pharmaceutical	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$88.00 ➝ $65.00
6/20/2025	RARE Ultragenyx Pharmaceutical	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$64.00
6/17/2025	PTCT PTC Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
6/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
5/28/2025	RARE Ultragenyx Pharmaceutical	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
5/27/2025	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$68.00 ➝ $74.00
5/9/2025	PTCT PTC Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$55.00 ➝ $68.00
5/9/2025	RARE Ultragenyx Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$64.00 ➝ $65.00
5/8/2025	PTCT PTC Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$56.00 ➝ $42.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$134.35M	25.69	N/A	N/A	$0.48 per share	82.54
AKBA Akebia Therapeutics	$160.18M	6.36	N/A	N/A	($0.23) per share	-16.87
PTCT PTC Therapeutics	$806.78M	4.77	N/A	N/A	($14.24) per share	-3.41
RARE Ultragenyx Pharmaceutical	$560.23M	4.63	N/A	N/A	$2.76 per share	9.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	-$55.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
AKBA Akebia Therapeutics	-$69.41M	-$0.21	N/A	N/A	N/A	-24.51%	N/A	-18.92%	8/6/2025 (Estimated)
PTCT PTC Therapeutics	-$363.30M	$6.51	7.45	N/A	N/A	33.56%	-78.56%	32.11%	8/6/2025 (Estimated)
RARE Ultragenyx Pharmaceutical	-$569.18M	-$5.88	N/A	N/A	N/A	-93.04%	-186.49%	-36.81%	7/30/2025 (Estimated)

Latest AKBA, PTCT, RARE, and AAPG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	AKBA Akebia Therapeutics	-$0.02	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	PTCT PTC Therapeutics	-$1.07	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	RARE Ultragenyx Pharmaceutical	-$1.27	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	AKBA Akebia Therapeutics	-$0.03	$0.03	+$0.06	$0.03	$44.88 million	$57.34 million
5/6/2025	Q1 2025	PTCT PTC Therapeutics	$0.85	$10.04	+$9.19	N/A	$437.16 million	$1.18 billion
5/6/2025	Q1 2025	RARE Ultragenyx Pharmaceutical	-$1.54	-$1.57	-$0.03	-$1.57	$145.98 million	$139.29 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	3.24	1.26	1.26
AKBA Akebia Therapeutics	1.89	2.23	2.02
PTCT PTC Therapeutics	N/A	3.89	3.85
RARE Ultragenyx Pharmaceutical	N/A	2.40	2.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
AKBA Akebia Therapeutics	33.92%
PTCT PTC Therapeutics	N/A
RARE Ultragenyx Pharmaceutical	97.67%

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
AKBA Akebia Therapeutics	3.00%
PTCT PTC Therapeutics	5.50%
RARE Ultragenyx Pharmaceutical	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	600	87.12 million	N/A	N/A
AKBA Akebia Therapeutics	430	262.64 million	254.76 million	Optionable
PTCT PTC Therapeutics	1,410	79.26 million	74.90 million	Optionable
RARE Ultragenyx Pharmaceutical	1,294	94.54 million	89.34 million	Optionable

AKBA, PTCT, RARE, and AAPG Headlines

Recent News About These Companies

Wedbush Brokers Decrease Earnings Estimates for RARE

51 minutes ago | americanbankingnews.com

Bank of America Securities Reiterated a Buy Rating on Ultragenyx Pharmaceutical (RARE)

July 17 at 11:53 AM | msn.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

July 17 at 10:00 AM | prnewswire.com

Wedbush Equities Analysts Reduce Earnings Estimates for RARE

July 17 at 7:16 AM | marketbeat.com

William Blair Issues Negative Forecast for RARE Earnings

July 17 at 4:54 AM | americanbankingnews.com

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Holdings Lowered by Bank of New York Mellon Corp

July 17 at 3:32 AM | marketbeat.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Down 5.7% on Analyst Downgrade

July 17 at 2:27 AM | americanbankingnews.com

FDA rejects Ultragenyx gene therapy over manufacturing concerns

July 16 at 8:33 PM | biopharmadive.comB

William Blair Maintains a Buy on Ultragenyx Pharmaceutical (RARE)

July 16 at 10:43 AM | insidermonkey.com

FY2025 EPS Estimates for RARE Cut by Cantor Fitzgerald

July 16 at 6:46 AM | marketbeat.com

William Blair Has Bearish Estimate for RARE FY2025 Earnings

July 16 at 6:46 AM | marketbeat.com

Wedbush Analysts Decrease Earnings Estimates for RARE

July 16 at 6:25 AM | marketbeat.com

Morgan Stanley Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price

July 16 at 4:09 AM | americanbankingnews.com

Ultragenyx hit again, this time with a CRL in rare disease

July 15 at 10:19 PM | bioworld.comB

Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA

July 15 at 10:19 PM | msn.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Trading Down 5.7% on Analyst Downgrade

July 15 at 11:57 AM | marketbeat.com

Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA

July 15 at 9:31 AM | zacks.com

Q4 EPS Forecast for Ultragenyx Pharmaceutical Cut by Analyst

July 15 at 8:23 AM | marketbeat.com

Ultragenyx: The High Stakes Of Binary Events And A Short Cash Runway

July 15 at 6:55 AM | seekingalpha.com

Ultragenyx Pharma Takes Another Hit As FDA Slaps Its Gene Therapy With A Rejection

July 14, 2025 | investors.com

Wedbush Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price

July 14, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500
By Sam Quirke | June 30, 2025
View Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500
Why Qualcomm’s Latest Price Target Can't Be Ignored
By Sam Quirke | June 24, 2025
View Why Qualcomm’s Latest Price Target Can't Be Ignored
MP Materials Stock Booms on New Government Positioning
By Gabriel Osorio-Mazilli | July 14, 2025
View MP Materials Stock Booms on New Government Positioning
Top 5 Undervalued Dividend Stocks With Strong Payout Potential
By Ryan Hasson | July 7, 2025
View Top 5 Undervalued Dividend Stocks With Strong Payout Potential

AKBA, PTCT, RARE, and AAPG Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$39.62 +1.00 (+2.59%)

As of 07/17/2025 03:57 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Akebia Therapeutics NASDAQ:AKBA

$3.88 -0.02 (-0.51%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$3.88 0.00 (-0.13%)

As of 07/17/2025 07:52 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

PTC Therapeutics NASDAQ:PTCT

$48.53 +0.39 (+0.81%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$48.54 +0.02 (+0.03%)

As of 07/17/2025 07:56 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Ultragenyx Pharmaceutical NASDAQ:RARE

$27.41 +0.10 (+0.37%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$27.58 +0.17 (+0.62%)

As of 07/17/2025 07:59 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time